Nektarios Barabutis

Associate Professor

School Basic Pharm & Toxicol Sci

PHAR 386

318-342-1460

Nektarios Barabutis, PhD
Associate Professor, School of Basic Pharmaceutical & Toxicological Sciences

Biographical Sketch

I am an Associate Professor of Pharmacology in ULM College of Pharmacy.

https://pubmed.ncbi.nlm.nih.gov/?term=barabutis&sort=date

Research Interests

https://pubmed.ncbi.nlm.nih.gov/?term=barabutis&sort=date

Recent Publications

Kubra, K., Barabutis, N. (2022). P53 in endothelial function and unfolded protein response regulation. Cell Biology International.

Kubra, K., Akhter, M. S., Saini, Y., Kousoulas, K. G., Barabutis, N. (2022). Activating transcription factor 6 protects against endothelial barrier dysfunction (pp. 110432). Cellular Signalling.

Barabutis, N. (2022). Unfolded protein response in endothelial injury (pp. 2009-2012). Cell Cycle.

Uddin, M. A., Akhter, M. S., Kubra, K., Barabutis, N. (2022). Hsp90 inhibition protects brain endothelial cells against LPS-induced injury (pp. 926-933). Biofactors.

Kubra, K., Uddin, M. A., Barabutis, N. (2022). Tunicamycin Protects against LPS-Induced Lung Injury. Pharmaceuticals.

Akhter, M. S., Kubra, K., Uddin, M. A., Jois, S. D., Barabutis, N. (2022). An antagonist of growth hormone‑releasing hormone protects against LPS‑induced increase of bronchoalveolar lavage fuid protein concentration (pp. 183-185). Inflammation Research.

Kubra, K., Uddin, M. A., Akhter, M. S., Leo, A. J., Siejka, A., Barabutis, N. (2021). P53 mediates the protective effects of metformin in inflamed lung endothelial cells (pp. 108367). International Immunopharmacology.

Akhter, M., Uddin, M., Kubra, K., Jois, S., Barabutis, N. (2022). An antagonist of Growth Hormone-Releasing Hormone protects against LPS-induced increase of bronchoalveolar lavage fluid protein concentration Inflammation Research (pp. 183-185). Inflammation Research.

Akhter, M. S., Barabutis, N. (2021). Suppression of reactive oxygen species in endothelial cells by an antagonist of growth hormone-releasing hormone. J Biochem Mol Toxicol.

Catravas, J., Dimitropoulou, C., Barabutis, N. (2018). The Hsp90 Inhibitor AUY-922 Reduces Pulmonary Fibrosis and Airway Dysfunction in Mice Exposed to HCl. American Thoracic Society.

Lazo, J. S., McQueeney, K., Salamoun, J., Barabutis, N., Catravas, J., Wipf, P. (2018). A potent and selective allosteric PTP4A3 phosphatase inhibitor enhances microvascular barrier function and inhibits human tumor cell growth. The FASEB Journal.

Uddin, M., Catravas, J., Barabutis, N. (2018). P53 enhances endothelial barrier function by suppressing APE1/Ref1. Monroe, LA: 18th Annual Student Research Symposium, University of Louisiana Monroe.

Uddin, M., Catravas, J., Barabutis, N. Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation. Baton Rouge, Louisiana: Louisiana Biomedical Research Network meeting.

Uddin, M., Catravas, J., Barabutis, N. (2019). Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation. Orlando, FL: The FASEB Journal.

Uddin, M., Barabutis, N. (2019). P53 Protects Blood Brain Barrier Against Hydrogen Peroxide Induced Breakdown. Miami, FL: Cerebral Vascular Biology Conference.

Kubra, K., Uddin, M., Akhter, M., Barabutis, N. (2020). Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells. Baton Rouge, Louisiana: Louisiana Biomedical Research Network meeting.

Uddin, M., Kubra, K., Barabutis, N. (2020). Unfolded protein response regulates P53 expression in pulmonary endothelium. Baton Rouge, Louisiana: Louisiana Biomedical Research Network meeting.

Akhter, M., Kubra, K., Uddin, M., Barabutis, N. (2020). Effect of Heat Shock Protein 90 Inhibition in Human Lung Microvascular Endothelial Cells. Baton Rouge, Louisiana: Louisiana Biomedical Research Network meeting.

Akhter, M., Kubra, K., Uddin, M., Barabutis, N. (2020). Unfolded Protein Response Regulates Pulmonary P53 Expression. San Diego, CA: The FASEB Journal.

Kubra, K., Uddin, M., Akhter, M., Barabutis, N. (2021). Luminespib counteracts the Kifunensine-induced lung endothelial barrier dysfunction. Baton Rouge, Louisiana: Louisiana Biomedical Research Network Annual Meeting.

Akhter, M., Uddin, M., Schally, A., Kubra, K., Barabutis, N. (2021). Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs. Baton Rouge, Louisiana: Louisiana Biomedical Research Network Annual Meeting.

Uddin, M., Akhter, M., Kubra, K., Barabutis, N. (2021). P53 deficiency potentiates LPS-Induced acute lung injury in vivo. Baton Rouge, Louisiana: Louisiana Biomedical Research Network Annual Meeting.

Uddin, M., Akhter, M., Kubra, K., Whitaker, K., Shipley, S., Smith, L., Barabutis, N. (2021). Hsp90 inhibition protects the brain microvascular endothelium against oxidative stress. Baton Rouge, Louisiana: Louisiana Biomedical Research Network Annual Meeting.

Kubra, K., Barabutis, N. (2021). Brefeldin A and Kifunensine modulate LPS-induced lung endothelial hyperpermeability in human and bovine cells. American Journal of Physiology - Cell Physiology.

Barabutis, N., Dimitropoulou, C., Gregory, B., Catravas, J. (2018). Wild-type p53 enhances endothelial barrier function by mediating RAC1 signalling and RhoA inhibition (pp. 13). Journal of Cellular and Molecular Medicine.

Barabutis, N., Schally, A., Siejka, A. (2018). P53, GHRH, inflammation and cancer (pp. 6). EBioMedicine.

Barabutis, N., Uddin, M., Catravas, J. (2018). Hsp90 inhibitors suppress P53 phosphorylation in LPS - induced endothelial inflammation (pp. 15). Cytokine.

Uddin, M., Barabutis, N. (2019). P53: The endothelium defender. J Cell Biochem.

Uddin, M., Akhter, M., Siejka, A., Catravas, J., Barabutis, N. (2019). P53 supports endothelial barrier function via APE1/Ref1 suppression. Immunobiology.

Akhter, M., Uddin, M., Barabutis, N. (2019). Unfolded protein response regulates P53 expression in the pulmonary endothelium. J Biochem Mol Toxicol.

Barabutis, N. (2019). Unfolded Protein Response Supports Endothelial Barrier Function. Biochimie.

Haynes, B., Yang, L. F., Huyck, R., Lehrer, E., Turner, J., Barabutis, N., Correll, V., Mathiesen, A., McPheat, W., Semmes, O. J., Dobrian, A. (2019). Endothelial to Mesenchymal Transition in Human Adipose Tissue Vasculature Alters the Particulate Secretome and Induces Endothelial Dysfunction. Arterioscler Thromb Vasc Biol.

Uddin, M., Akhter, M., Singh, S., Kubra, K., Schally, A., Jois, S., Barabutis, N. (2019). GHRH antagonists support lung endothelial barrier function. Tissue Barriers.

Barabutis, N. (2019). Unfolded Protein Response in Acute Respiratory Distress Syndrome. Lung.

Akhter, M., Uddin, M., Kubra, K., Barabutis, N. (2019). P53-induced reduction of lipid peroxidation supports brain microvascular endothelium integrity. Journal of Pharmacological Sciences.

Kubra, K., Uddin, M., Akhter, M., Barabutis, N. (2019). Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells.

Akhter, M., Uddin, M., Barabutis, N. (2019). P53 Regulates the Redox Status of Lung Endothelial Cells. Inflammation.

Kubra, K., Akhter, M., Uddin, M., Barabutis, N. (2019). P53 versus inflammation: an update. Cell Cycle.

Barabutis, N. (2020). Heat shock protein 90 inhibition in the inflamed lungs. Cell Stress Chaperones.

Barabutis, N. (2020). Growth hormone releasing hormone in the unfolded protein response context. Endocrine.

Barabutis, N. (2020). Regulation of lung endothelial permeability by NEK kinases. IUBMB Life ..

Barabutis, N. (2020). P53 in RhoA regulation. Cytoskeleton.

Barabutis, N., Siejka, A. (2020). The highly interrelated GHRH, p53, and Hsp90 universe. Cell Biology International.

Barabutis, N. (2020). A glimpse at growth hormone-releasing hormone cosmos. Clin Exp Pharmacol Physiol ..

Barabutis, N., Akhter, M., Uddin, M., Kubra, K., Schally, A. (2020). GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity. Hormone and Metabolic Research.

Kubra, K., Akhter, M., Uddin, M., Barabutis, N. (2020). Unfolded protein response in cardiovascular disease (pp. 6). Cellular Signalling.

Barabutis, N. (2020). P53 in lung vascular barrier dysfunction (pp. 2). Vascular biology.

Uddin, M., Akhter, M., Kubra, K., Barabutis, N. (2020). P53 deficiency potentiates LPS-Induced acute lung injury in vivo (pp. 3). Current Research in Physiology.

Uddin, M., Kubra, K., Sonju, J. J., Akhter, M., Seetharama, J., Barabutis, N. (2020). Effects of Heat Shock Protein 90 Inhibition In the Lungs (pp. 17). Med Drug Discov.

Kubra, K., Akhter, M., Uddin, M., Barabutis, N. (2020). Kifunensine compromises lung endothelial barrier function. Microvascular Research Volume 132, November 2020, 104051.

Kubra, K., Uddin, M., Akhter, M., Barabutis, N. (2020). P53 is Subjected to Lipoteichoic Acid-Induced Phosphorylation in the Lungs (pp. 2). TH Open.

Uddin, A., Barabutis, N. (2020). P53 in the impaired lungs. DNA Repair.

Barabutis, N. (2020). Unfolded Protein Response in Lung Health and Disease (pp. 6). Frontiers in Medicine.

Barabutis, N. (2020). P53 in acute respiratory distress syndrome (pp. 3). Cellular and Molecular Life Sciences.

Barabutis, N., Margarita, M., Solopov, P., Uddin, M., Croston, G., Reinheimer, T., Catravas, J. (2020). Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction (pp. 286-295). Journal of Pharmacology and Experimental Therapeutics.

Kubra, K., Uddin, M., Akhter, M., Barabutis, N. (2020). Luminespib counteracts the Kifunensine-induced lung endothelial barrier dysfunction (pp. 5). Current Research in Toxicology.

Akhter, M., Uddin, M., Kubra, K., Barabutis, N. (2021). Autophagy, Unfolded Protein Response and Lung Disease (pp. 22). Current Research in Cell Biology.

Uddin, M., Akhter, M., Kubra, K., Barabutis, N. (2021). Induction of the NEK family of kinases in the lungs of mice subjected to cecal ligation and puncture model of sepsis.

Akhter, M., Uddin, M., Schally, A., Kubra, K., Barabutis, N. (2020). Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs (pp. 5). Journal of Cell Communication and Signaling.

Uddin, M., Akhter, M., Kubra, K., Siejka, A., Barabutis, N. (2020). Metformin in acute respiratory distress syndrome: An opinion (pp. 3). Experimental Gerontology.

Barabutis, N. (2020). Unfolded protein response in the COVID-19 context (pp. 2). Aging and Health Research.

Uddin, M., Akhter, M., Kubra, K., Whitaker, K., Shipley, S., Smith, L., Barabutis, N. (2020). Hsp90 inhibition protects the brain microvascular endothelium against oxidative stress. Brain Disorders.

Barabutis, N. (2021). Insights on supporting the aging brain microvascular endothelium (pp. 3). Aging Brain.

Barabutis, N. (2021). Growth Hormone Releasing Hormone in Endothelial Barrier Function (pp. 3). Trends in Endocrinology & Metabolism.

Barabutis, N. (2021). Unfolded Protein Response: A Regulator of the Endothelial Barrier (pp. 2). Endocrine and Metabolic Science.

Barabutis, N., Akhter, M., Kubra, K., Uddin, M. (2021). Restoring the endothelial barrier function in the elderly (pp. 2). Mechanisms of Ageing and Development.

Siejka, A., Barabutis, N. (2021). Adrenal insufficiency in the COVID-19 era. (pp. 2). American Journal of Physiology-Endocrinology and Metabolism.

Akhter, M., Uddin, M., Kubra, K., Barabutis, N. (2021). Share Elucidation of the Molecular Pathways Involved in the Protective Effects of AUY-922 in LPS-Induced Inflammation in Mouse Lungs (pp. 14). Basel: Pharmaceuticals..

Research Grants

Barabutis, N. (Principal), "Unfolded protein response-mediated regulation of lung endothelial permeability" (Funded), Sponsored By LA Board of Regents, External to The University of Louisiana at Monroe, $19000. (2021 - Present).

Barabutis, N., "Somatostatin analogs in endothelial hyperpermeability" (Funded), Sponsored By LBRN, $72,500. (2023 - 2024).

Barabutis, N. (Co-Principal), "Protective role of ATF6 against endothelial barrier dysfunction" (Funded), Sponsored By Louisiana Biomedical Research Network/NIGMS, $80,088. (May 2021 - April 2022).

Barabutis, N. (Principal), "NEK kinases: A novel target in lung inflammatory disease" (), Sponsored By College of Pharmacy, The University of Louisiana at Monroe, $. (2021 - 2022).

Barabutis, N. (Principal), "Activation of the Unfolded Protein Response protects against LPS - induced lung endothelial barrier dysfunction" (Funded), Sponsored By Louisiana Board of Regents, External to The University of Louisiana at Monroe, $140286. (2019 - 2022).

, "Growth Hormone Releasing Hormone Antagonists Induce the Unfolded Protein Response" (), Sponsored By College of Pharmacy, The University of Louisiana at Monroe, $. (2020 - 2021).

Barabutis, N., "Elucidation of the mechanisms which are involved in the anti-inflammatory action of Hsp90 inhibitors in the vasculature" (Funded), Sponsored By Louisiana Biomedical Research Network, External to The University of Louisiana at Monroe, $60250. (2018 - 2020).

Barabutis, N., "Elucidation of the mechanisms which mediate the protective role of P53 against inflammation" (), Sponsored By College of Pharmacy, The University of Louisiana at Monroe, $. (2018 - 2019).

Barabutis, N. (Co-Principal), Alexander, S. (Principal), "Elucidation of the mechanisms that mediate the protective action of wild type P53 on brain endothelial barrier function" (), Sponsored By LSU Health Shrevenport, External to The University of Louisiana at Monroe, $25000. (2018 - 2019).

Awards & Honors

Excellence in Team Teaching Award, ULM College of Pharmacy (2022)..

2021 3rd Year Pharmacy Team Taught Class Excellence in Teaching Award .

2020 Excellence in Team Teaching Award .

2016 The Hermann Rahn Award for Excellence in Pulmonary Research.

2015 APS Select Award for distinction in Scholarship.

Courses Taught

PHAR 5036INTRO STATISTICAL SOFTWARE, 3 course(s)

PHRD 4008PHARMACEUTICS I, 5 course(s)

PHRD 4027PRINCIPLES OF DRUG ACTION II, 6 course(s)

PHRD 4035PATHOPHYSIOLOGY II, 6 course(s)

PHRD 4072THERAPEUTICS II, 5 course(s)

PHRD 5027BONE AND JOINT MODULE, 1 course(s)

PHRD 5039THERAPEUTICS VII, 4 course(s)

PHRD 5064PROBLEMS, 4 course(s)